A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
The primary purpose of this study is to identify an appropriate dose of study medication.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Charlotte, North Carolina 28204, United States
Kitakyushu-shi, Fukuoka 8078555, Japan
Kato-shi, Hyōgo 6731462, Japan
Sasebo-shi, Nagasaki 8571195, Japan
Shinjuku-Ku, Tokyo 1608582, Japan
Toshima-ku, Tokyo 1708476, Japan
Nishimura, Wakayama 6492211, Japan